Family Building by Same-Sex Male Couples via Gestational Surrogacy

Abstract

Best estimates suggest that the number of households with same-sex male couples is increasing. One option for family building by same-sex male couples is gestational surrogacy. Embryos would be generated in vitro, using the biologic father's sperm with donor oocytes, and another woman (the gestational carrier) would undergo an embryo transfer to bear a child. Conceiving via gestational surrogacy requires advance planning, not only to coordinate the oocyte donor and gestational carrier but also to comply with regulations set forth by the Food and Drug Administration (FDA). The American Society for Reproductive Medicine (ASRM) has also published recommendations for practices using gestational carriers, which, in many cases, are more stringent than the FDA regulations. This article will review the FDA regulations and ASRM recommendations and their implications for same-sex male couples who plan to conceive via gestational surrogacy.

Keywords

gestational carrier - surrogacy - gay men - gay father - same-sex couples - third-party reproduction - assisted reproduction - sperm donor

• References

• 1 ACS. Characteristics of Same-Sex Couple Households: 2005 to Present: U.S. Census Bureau; 2017 [updated April 7, 2017; cited August 20, 2017]. Available at: https://www.census.gov/data/tables/time-series/demo/same-sex-couples/ssc-house-characteristics.html . Accessed September 20, 2017
• 2 ACS. Characteristics of Same-Sex Couple Households: 2005 to Present: U.S. Census Bureau; 2015 [updated April 7, 2017; cited August 20, 2017]. Available at: https://www.census.gov/data/tables/time-series/demo/same-sex-couples/ssc-house-characteristics.html . Accessed August 20, 2017
• 3 Ethics Committee of the American Society for Reproductive Medicine. Consideration of the gestational carrier: a committee opinion. Fertil Steril 2013; 99 (07) 1838-1841
• 4 Ryan GL. ; American College of Obstetricians and Gynecologists' Committee on Ethics. ACOG Committee Opinion No. 660 Summary: Family building through gestational surrogacy. Obstet Gynecol 2016; 127 (03) 620-621
• 5 Ethics Committee of the American Society for Reproductive Medicine. Electronic address: [e-mail]; Ethics Committee of the American Society for Reproductive Medicine. Using family members as gamete donors or gestational carriers. Fertil Steril 2017; 107 (05) 1136-1142
• 6 Ethics Committee of American Society for Reproductive Medicine. Access to fertility treatment by gays, lesbians, and unmarried persons: a committee opinion. Fertil Steril 2013; 100 (06) 1524-1527
• 7 Practice Committee of the American Society for Reproductive Medicine and Practice Committee of the Society for Assisted Reproductive Technology. Electronic address: [e-mail]; Practice Committee of the American Society for Reproductive Medicine and Practice Committee of the Society for Assisted Reproductive Technology. Recommendations for practices utilizing gestational carriers: a committee opinion. Fertil Steril 2017; 107 (02) e3-e10
• 8 Blake L, Carone N, Raffanello E, Slutsky J, Ehrhardt AA, Golombok S. Gay fathers' motivations for and feelings about surrogacy as a path to parenthood. Hum Reprod 2017; 32 (04) 860-867
• 9 Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. Lancet 1978; 2 (8085): 366
• 10 Lutjen P, Trounson A, Leeton J, Findlay J, Wood C, Renou P. The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. Nature 1984; 307 (5947): 174-175
• 11 Utian WH, Sheean L, Goldfarb JM, Kiwi R. Successful pregnancy after in vitro fertilization and embryo transfer from an infertile woman to a surrogate. N Engl J Med 1985; 313 (21) 1351-1352
• 12 Perkins KM, Boulet SL, Jamieson DJ, Kissin DM. ; National Assisted Reproductive Technology Surveillance System (NASS) Group. Trends and outcomes of gestational surrogacy in the United States. Fertil Steril 2016; 106 (02) 435-442.e2
• 13 CDC. 2014 Assisted Reproductive Technology National Summary Report: US Department of Health and Human Services; 2016. Available at: https://www.cdc.gov/art/pdf/2014-report/art-2014-national-summary-report.pdf . Accessed September 20, 2017
• 14 Kushnir VA, Darmon SK, Shapiro AJ, Albertini DF, Barad DH, Gleicher N. Utilization of third-party in vitro fertilization in the United States. Am J Obstet Gynecol 2017; 216 (03) 266.e1-266.e10
• 15 Fuchs EL, Berenson AB. Screening of gestational carriers in the United States. Fertil Steril 2016; 106 (06) 1496-1502
• 16 James S, Chilvers R, Havemann D, Phelps JY. Avoiding legal pitfalls in surrogacy arrangements. Reprod Biomed Online 2010; 21 (07) 862-867
• 17 Creative Family Connections. Gestational Surrogacy Law across the United States Chevy Chase, MD 2017 [September 10, 2017]. Available at: https://www.creativefamilyconnections.com/us-surrogacy-law-map/ . Accessed September 20, 2017
• 18 FDA. FDA Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P's) Product List: US Food and Drug Administration; 2009 [updated May 12, 2009; cited August 18, 2017]. Available at: https://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/RegulationofTissues/ucm150485.htm . Accessed September 20, 2017
• 19 FDA. Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry: US Food and Drug Administration; 2007 [updated August 2017]. Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM091345.pdf . Accessed September 20, 2017
• 20 FDA. Section 1271.1 of Subpart A (General Provisions): U.S. Food and Drug Administration; 2017 [updated August 14, 2017; cited August 18, 2017]. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1271.1 . Accessed September 20, 2017
• 21 FDA. Part 1271 (Human Cells, Tissues, and Cellular and Tissue-Based Products): U.S. Food and Drug Administration; 2017 [updated August 14, 2017; cited August 18, 2017]. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1271 . Accessed September 20, 2017
• 22 FDA. Donor Eligibility Final Rule and Guidance Questions and Answers: Food and Drug Administration; 2009 [updated April 20, 2009; cited August 18, 2017]. Available at: https://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/QuestionsaboutTissues/ucm102842.htm . Accessed September 20, 2017
• 23 FDA. Section 1271.45 of Subpart C (Donor Eligibility): U.S. Food and Drug Administration; 2017 [updated August 14, 2017; cited August 18, 2017]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1271.45 . Accessed September 20, 2017
• 24 FDA. Section 1271.90 of Subpart C (Donor Eligibility): U.S. Food and Drug Administration; 2017 [updated August 14, 2017; cited August 18, 2017]. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1271.90 . Accessed September 20, 2017
• 25 FDA. Section 1271.3 of Subpart A (General Provisions): U.S. Food and Drug Administration; 2017 [updated August 14, 2017; cited August 18, 2017]. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1271.3 . Accessed September 20, 2017
• 26 FDA. Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products: Guidance for Industry: US Food and Drug Administration; 2016 [September 2017]. Available from: https://www.fda.gov/downloads/biologicsbloodvaccines/.../tissue/ucm488582.pdf . Accessed September 20, 2017
• 27 FDA. Testing HCT/P Donors for Relevant Communicable Disease Agents and Diseases: U.S. Food and Drug Administration; 2017 [updated February 22, 2017; cited August 18, 2017]. Available at: https://www.fda.gov/biologicsbloodvaccines/safetyavailability/tissuesafety/ucm095440.htm . Accessed September 20, 2017
• 28 FDA. Section 1271.65 of Subpart C (Donor Eligibility): U.S. Food and Drug Administration; 2017 [updated 08/14/2017; cited August 18, 2017]. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1271.65 . Accessed September 20, 2017
• 29 Sohn E. Shots: Health News From NPR [Internet]. Washington, DC: NPR; 2017. Available at: http://www.npr.org/sections/health-shots/2017/03/10/519436501/states-wrestle-with-legalizing-payments-for-gestational-surrogates?utm_source=npr_newsletter&utm_medium=email&utm_content=20170909&utm_campaign=npr_email_a_friend&utm_term=storyshare . Accessed September 20, 2017
• 30 Dunn J. California law supports surrogacy for gay and straight couples with fertility issues. North Bay Business Journal. August 28, 2017
• 31 Klitzman RL, Sauer MV. Kamakahi vs ASRM and the future of compensation for human eggs. Am J Obstet Gynecol 2015; 213 (02) 186-187.e1
• 32 Ethics Committee of the American Society for Reproductive Medicine. Financial compensation of oocyte donors. Fertil Steril 2007; 88 (02) 305-309
• 33 Ethics Committee of the American Society for Reproductive Medicine. Electronic address: [e-mail]; Ethics Committee of the American Society for Reproductive Medicine. Financial compensation of oocyte donors: an Ethics Committee opinion. Fertil Steril 2016; 106 (07) e15-e19
• 34 Lewin T. Egg donors challenge pay rates, saying they shortchange women. The New York Times. October 17, 2015
• 35 Bonner J. Judge tosses demand for FDA-barred sperm. Courthouse News. July 19, 2013